LenvimaLenvatinib10 mgthirtyТаб Thyroid Cancer: Progressive, radioactive iodine-refractory differentiated thyroid cancer.Renal Cell Carcinoma (RCC): First-line with pembrolizumab, or with everolimus after prior anti-angiogenic therapy.Hepatocellular Carcinoma (HCC): First-line treatment for unresectable disease.Endometrial Carcinoma: In combination with pembrolizumab for advanced, non-MSI-H/dMMR cases following prior therapy.
Thyroid Cancer: Progressive, radioactive iodine-refractory differentiated thyroid cancer.Renal Cell Carcinoma (RCC): First-line with pembrolizumab, or with everolimus after prior anti-angiogenic therapy.Hepatocellular Carcinoma (HCC): First-line treatment for unresectable disease.Endometrial Carcinoma: In combination with pembrolizumab for advanced, non-MSI-H/dMMR cases following prior therapy.
